PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 4 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $68,000 | -90.4% | 17,779 | -84.6% | 0.00% | -71.4% |
| Q2 2019 | $712,000 | +4.1% | 115,461 | -21.7% | 0.01% | 0.0% |
| Q1 2019 | $684,000 | -12.8% | 147,476 | -21.0% | 0.01% | -22.2% |
| Q4 2018 | $784,000 | -11.7% | 186,619 | +56.9% | 0.01% | -35.7% |
| Q1 2018 | $888,000 | +115.5% | 118,973 | +71.6% | 0.01% | +100.0% |
| Q4 2017 | $412,000 | +12.9% | 69,312 | +39.9% | 0.01% | 0.0% |
| Q3 2017 | $365,000 | -43.5% | 49,544 | -47.9% | 0.01% | -46.2% |
| Q2 2017 | $646,000 | +25.9% | 95,132 | +75.2% | 0.01% | -7.1% |
| Q1 2017 | $513,000 | +46.6% | 54,299 | +33.9% | 0.01% | 0.0% |
| Q4 2016 | $350,000 | +400.0% | 40,559 | +265.4% | 0.01% | +180.0% |
| Q3 2016 | $70,000 | -72.3% | 11,099 | -73.1% | 0.01% | -82.1% |
| Q4 2015 | $253,000 | +57.1% | 41,300 | +53.1% | 0.03% | -50.0% |
| Q1 2015 | $161,000 | – | 26,972 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |